Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984082 | 1.00 | MAPT (0.57) | MAPTKMT2AMEN1ADRB2ADRB1 | |
| SCHEMBL2988615 | 1.00 | MAPT (0.57) | MAPTKMT2AMEN1ADRB2ADRB1 | |
| SCHEMBL1965809 | 0.91 | CA12 (0.53) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL4736415 | 0.85 | CA12 (0.48) | MAPTKMT2ACA12CA1CA2 | |
| SCHEMBL9724886 | 0.84 | CA12 (0.67) | MAPTKMT2AMEN1ADRB2ADRB1 | |
| SCHEMBL13784553 | 0.84 | CA1 (0.52) | MAPTKMT2AMEN1CA12CA1 | |
| SCHEMBL92240 | 0.84 | L3MBTL1 (0.55) | MAPTKMT2AMEN1ADRB2ADRB1 | |
| SCHEMBL716832 | 0.84 | MAPT (0.60) | MAPTKMT2ACA12CA1CA2 | |
| SCHEMBL10705086 | 0.84 | CYP4F2 (0.53) | MAPTCA12CA1CA2CA7 | |
| SCHEMBL39298 | 0.84 | CA12 (0.67) | MAPTKMT2AMEN1ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751087-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | Xenoport, Inc. (US) | 2007-02-14 | — | — | EP | claimed |
| WO-2005121069-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20230167130-A1 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | AMGEN INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2008034087-A2 | TREATING SCHIZOPHRENIA WITH COMBINATIONS OF LEVODOPA AND AN ANTIPSYCHOTIC AGENT | XENOPORT, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167130-A1 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | MCL1, BAK1, BCLAF1 | MAPT 3886/4885KMT2A 1280/4885MEN1 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.